"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
Descriptor ID |
D016190
|
MeSH Number(s) |
D02.691.800.338
|
Concept/Terms |
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
|
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in this website by year, and whether "Carboplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 2 | 3 |
1995 | 3 | 4 | 7 |
1996 | 4 | 1 | 5 |
1997 | 1 | 6 | 7 |
1998 | 1 | 1 | 2 |
1999 | 1 | 6 | 7 |
2000 | 2 | 6 | 8 |
2001 | 2 | 6 | 8 |
2002 | 2 | 10 | 12 |
2003 | 2 | 3 | 5 |
2004 | 1 | 12 | 13 |
2005 | 3 | 8 | 11 |
2006 | 4 | 7 | 11 |
2007 | 3 | 6 | 9 |
2008 | 3 | 10 | 13 |
2009 | 3 | 17 | 20 |
2010 | 6 | 18 | 24 |
2011 | 2 | 17 | 19 |
2012 | 4 | 10 | 14 |
2013 | 6 | 15 | 21 |
2014 | 4 | 8 | 12 |
2015 | 6 | 14 | 20 |
2016 | 2 | 12 | 14 |
2017 | 5 | 9 | 14 |
2018 | 3 | 12 | 15 |
2019 | 3 | 19 | 22 |
2020 | 4 | 9 | 13 |
2021 | 3 | 14 | 17 |
2022 | 0 | 9 | 9 |
2023 | 0 | 10 | 10 |
2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial. Nat Commun. 2024 Feb 23; 15(1):1650.
-
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024 Mar 11; 42(3):429-443.e4.
-
Dietary Magnesium Replacement for Prevention of Hypomagnesemia in Patients With Ovarian Cancer Receiving Carboplatin-Based Chemotherapy. JCO Oncol Pract. 2024 Apr; 20(4):517-524.
-
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024 Mar; 200:113580.
-
Angiographic characteristics and treatment approach in patients undergoing intra-arterial chemotherapy for retinoblastoma. Graefes Arch Clin Exp Ophthalmol. 2024 Apr; 262(4):1321-1328.
-
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 12; 186:107418.
-
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024 Jan 20; 42(3):283-299.
-
Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study. Int J Gynecol Cancer. 2023 09 04; 33(9):1359-1369.
-
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med. 2023 05; 13(5):e1267.
-
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 06 08; 388(23):2145-2158.